Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice

Cytotherapy

Volumn 18, Issue 2, 2015, Pages 219-228

  Koch, Jill M ^a   D'Souza, Saritha S ^b   Schwahn, Denise J ^c   Dixon, Ian ^d   Hacker, Timothy A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Cynata Therapeutics Limited   (Australia)

Author keywords

critical limb ischemia; hindlimb ischemia; induced pluripotent stem cells; mesenchymal stem cells; peripheral arterial disease; stem cell therapy

Indexed keywords

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CAPILLARY; CELL DAMAGE; CELL DIFFERENTIATION; CENTRALIZATION; CONTROLLED STUDY; DEGENERATION; EMBRYO; FATTY DEGENERATION; FEMORAL ARTERY; FIBROSIS; GASTROCNEMIUS MUSCLE; HINDLIMB ISCHEMIA; HUMAN; ILIAC ARTERY; INCIDENCE; INDUCED PLURIPOTENT STEM CELL; LIMB BLOOD FLOW; LIMB INJURY; LIMB ISCHEMIA; MESENCHYMAL STROMA CELL; MESENCHYMOANGIOBLAST; MOUSE; NECROSIS; NONHUMAN; NUCLEAR CENTRALIZATION; PERIPHERAL CIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TISSUE INJURY; TOE NECROSIS; ANIMAL; BLOOD FLOW; CYTOLOGY; GROWTH, DEVELOPMENT AND AGING; HINDLIMB; INJURIES; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; PHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SKELETAL MUSCLE; VASCULARIZATION;

ANIMALS; CELL DIFFERENTIATION; FEMORAL ARTERY; HINDLIMB; ILIAC ARTERY; INDUCED PLURIPOTENT STEM CELLS; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MUSCLE, SKELETAL; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS;

EID: 84991404919     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.10.013     Document Type: Article

References (28)

1. [1] Abdulhannan, P., Russell, D.A., Homer-Vanniasinkam, S., Peripheral arterial disease: a literature review. Br Med Bull 104 (2012), 21–39.
2. [2] Selvin, E., Erlinger, T.P., Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110 (2004), 738–743.
3. [3] Raval, Z., Losordo, D.W., Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res 112 (2013), 1288–1302.
4. [4] Golomb, B.A., Dang, T.T., Criqui, M.H., Peripheral arterial disease: morbidity and mortality implications. Circulation 114 (2006), 688–699.
5. [5] Liew, A., O'Brien, T., Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther, 3, 2012, 28.
6. [6] Lawall, H., Bramlage, P., Amann, B., Stem cell and progenitor cell therapy in peripheral artery disease. Thromb Haemost 103 (2010), 696–709.
7. [7] Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringdén, O., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:10 (2003), 890–896.
8. [8] Karantalis, V., Hare, J.M., Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 116 (2015), 1413–1430.
9. [9] Wagner, W., Horn, P., Castoldi, M., Diehlmann, A., Bork, S., Saffrich, R., et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE, 3(5), 2008, e2213.
10. [10] Phinney, D.D., Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 113 (2012), 2806–2812.
11. [11] Lei, Y., Schaffer, D.V., A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc Natl Acad Sci USA 110 (2013), E5039–48.
12. [12] Rufaihah, A.J., Huang, N.F., Jamé, S., Lee, J.C., Nguyen, H.N., Byers, B., et al. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol 31 (2011), e72–9.
13. [13] Lai, W.H., Ho, J.C., Chan, Y.C., Ng, J.H., Au, K.W., Wong, L.Y., et al. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. PLoS ONE, 8(3), 2013, e57876.
14. [14] Dar, A., Domev, H., Ben-Yosef, O., Tzukerman, M., Zeevi-Levin, N., Novak, A., et al. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 125:1 (2012), 87–99.
15. [15] Lian, Q., Zhang, Y., Zhang, J., Zhang, H.K., Wu, X., Zhang, Y., et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 121:9 (2010), 1113–1123.
16. [16] Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Krause, D.S., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317.
17. [17] Lian, Q., Lye, E., Suan Yeo, K., Khia Way Tan, E., Salto-Tellez, M., Liu, T.M., et al. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 25:2 (2007), 425–436.
18. [18] Takashima, Y., Era, T., Nakao, K., Kondo, S., Kasuga, M., Smith, A.G., et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129 (2007), 1377–1388.
19. [19] Dennis, J.E., Charbord, P., Origin and differentiation of human and murine stroma. Stem Cells 20 (2002), 205–214.
20. [20] Isern, J., García-García, A., Martín, A.M., Arranz, L., Martín-Pérez, D., Torroja, C., et al. The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. eLife, 3, 2014, e03696.
21. [21] Vodyanik, M.A., Yu, J., Zhang, X., Tian, S., Stewart, R., Thomson, J., et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 7 (2010), 718–729.
22. [22] Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007), 1917–1920.
23. [23] Mendicino, M., Bailey, A.M., Wonnacott, K., Puri, R.K., Bauer, S.R., MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 14 (2014), 141–145.
24. [24] Sharma, R.R., Pollock, K., Hubel, A., McKenna, D., Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion, 2014, 1418–1437.
25. [25] Simons, M., Angiogenesis: where do we stand now?. Circulation 11 (2005), 1556–1566.
26. [26] Shireman, P.K., The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 45:Suppl. A (2007), A48–56.
27. [27] Korthuis, R.J., Skeletal muscle circulation. 2011, Morgan & Claypool Life Sciences, San Rafael (CA).
28. [28] Limbourg, A., Korff, T., Napp, L.C., Schaper, W., Drexler, H., Limbourg, F.P., Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 4 (2009), 1737–1746.